UCB

UCB, a global biopharmaceutical company, was founded in 1928 and is headquartered in Brussels, Belgium. The company is dedicated to discovering, developing, and commercializing innovative medicines for individuals facing severe neurological and autoimmune conditions. UCB's strategic focus encompasses neurology, including epilepsy and Parkinson's disease, and immunology, addressing conditions such as rheumatoid arthritis, Crohn's disease, psoriasis, and axial spondyloarthritis. UCB operates in over 40 countries, aiming to create sustainable value and improve health equity. Learn about UCB's global headquarters for detailed geographic information.

The company's extensive product portfolio includes key treatments such as Cimzia, Vimpat, Keppra, Briviact, Neupro, Bimzelx, Evenity, and Fintepla. UCB employs over 10,000 individuals across its global operations, integrating patient and caregiver insights directly into its research and development processes. This approach ensures that scientific advancements are aligned with the real-world needs of patients. The company's U.S. headquarters are located in Smyrna, Georgia, with additional sites supporting critical functions like clinical development and research. Meet UCB's team to understand the expertise driving their therapeutic innovations.

UCB's operational footprint extends across more than 40 countries, underscoring its global reach in addressing unmet medical needs. The company's revenue reached $5.9 billion, reflecting its significant market presence in the biopharmaceutical sector. UCB's dedication to health equity and sustainable value creation is a cornerstone of its corporate strategy, aiming to make a tangible difference in the lives of patients worldwide. Its competitive landscape includes major players like Pfizer, Amgen, and Lilly, highlighting UCB's position within the biopharmaceutical industry.